Paper1605902
Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate).
Eyres KS and 4 others. Drug Saf, 1992. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Papers, record 1605902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1605902
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate).
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Etidronic Acid | Major topic |
| Fractures, Spontaneous | Major topic |
| Osteitis Deformans | Major topic |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Femoral Neck Fractures | |
| Humans | |
| Osteomalacia | |
| Tibial Fractures |
Source PubMed
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6820112 | Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone. | Metab Bone Dis Relat Res | 1981 | https://conductscience.org/library/papers/6820112 | PubMed |
| 2 | 6401608 | Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP). | Clin Orthop Relat Res | 1983 | https://conductscience.org/library/papers/6401608 | PubMed |
| 3 | 52045 | Letter: Disodium ethane-1-hydroxy-1, 1-diphosphonate(E.H.D.P.) in Paget's disease. | Lancet | 1975 | https://conductscience.org/library/papers/52045 | PubMed |
| 4 | 4201876 | Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). | N Engl J Med | 1973 | https://conductscience.org/library/papers/4201876 | PubMed |
| 5 | 4206518 | Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment. | Q J Med | 1973 | https://conductscience.org/library/papers/4206518 | PubMed |
| 6 | 86042 | Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). | Lancet | 1979 | https://conductscience.org/library/papers/86042 | PubMed |
| 7 | 6101833 | Calcitonin or diphosphonates for osteolytic Paget's disease? | Lancet | 1980 | https://conductscience.org/library/papers/6101833 | PubMed |
| 8 | 4213513 | Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate. | JAMA | 1974 | https://conductscience.org/library/papers/4213513 | PubMed |
| 9 | 2863616 | Etidronate and the risk of fractures. | Lancet | 1985 | https://conductscience.org/library/papers/2863616 | PubMed |
| 10 | 401827 | Diphosphonate therapy of paget's disease of bone. | J Clin Endocrinol Metab | 1977 | https://conductscience.org/library/papers/401827 | PubMed |
| 11 | 6220190 | Paget's disease of bone: diagnosis and management. | Metab Bone Dis Relat Res | 1981 | https://conductscience.org/library/papers/6220190 | PubMed |
| 12 | 3085989 | Absorption of oral diphosphonate in normal subjects. | Clin Endocrinol (Oxf) | 1986 | https://conductscience.org/library/papers/3085989 | PubMed |
| 13 | 412450 | Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. | Ann Intern Med | 1977 | https://conductscience.org/library/papers/412450 | PubMed |
| 14 | 410576 | Treatment of Paget's disease of bone (osteitis deformans) with sodium etidronate (EHDP). | Clin Orthop Relat Res | 1977 | https://conductscience.org/library/papers/410576 | PubMed |
| 15 | 6143140 | Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. | Lancet | 1984 | https://conductscience.org/library/papers/6143140 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 17503893 | Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date. | Drugs Aging | 2007 | https://conductscience.org/library/papers/17503893 | PubMed |
| 12184516 | What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. | Dig Dis Sci | 2002 | https://conductscience.org/library/papers/12184516 | PubMed |
| 11595119 | The role of bisphosphonates as adjuvant therapy for breast cancer. | Curr Oncol Rep | 2001 | https://conductscience.org/library/papers/11595119 | PubMed |
| 7858370 | Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. | Drugs Aging | 1994 | https://conductscience.org/library/papers/7858370 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1605902
GET https://conductscience.org/api/papers/v1/1605902/authors